Currently, plentiful therapeutics for SLE treatment have achieved remarkable results in clinical trials by attenuating immune response through multiple targets, including Toll‐like receptor inhibitors, anti‐malarial agents (such as hydroxychloroquine that blocks TLR binding epitopes), blocking antibodies (such as IFN‐α, CD40, CD19, CD20, and FcRIIb), molecular agents (such as JAK1 inhibitor and STAT1 and STAT3 inhibitors), and autologous and allogeneic CD19 CAR‐T cells [50]. Here, STAT1 is linked to systemic lupus erythematosus.